▎药明康德内容团队编辑BavarianNordic今日宣布，欧盟委员会已批准Vimkunya（基孔肯雅热重组疫苗），用于建立主动免疫，以预防12岁及以上人群感染基孔肯雅热病毒（CHIKV）所致的疾病。根据新闻稿，该疫苗是首个在欧洲获批适用于12岁及以 ...

Experts at BJMC and SGH are sequencing Chikungunya virus to investigate mutations linked to severe cases and outbreaks in ...

Future Virology. 2008;3(2):179-192. Although not listed as a hemorrhagic fever virus, illness caused by CHIKV can be confused with diseases such as dengue or yellow fever, based on the similarity ...

Bavarian Nordic recently expanded its global commercial presence to include a dedicated UK-based organization to manage its travel health portfolio, also comprising vaccines for rabies, typhoid and ...

Biological E (BE) has partnered with Bavarian Nordic to produce the Chikungunya vaccine, VIMKUNYA CHIKV VLP, for low and ...

The European Commission on Friday authorized a vaccine against the chikungunya virus - a mosquito-borne disease - for adults and young people aged 12 and over. "The commission is determined to use all ...

The accelerated approval was granted based on anti-CHIKV neutralizing antibody levels; continued approval may be contingent upon verification of benefit in a confirmatory trial. The Food and Drug ...

Copenhagen, Denmark Monday, March 10, 2025, 11:00 Hrs [IST] ...

COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA ® for active ...

CHIKV VLP vaccine was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025 under the trade name VIMKUNYA ®, and could potentially obtain approval ...

If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – ...